| Bioactivity | Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB). Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2]. | ||||||||||||
| Name | Neridronate | ||||||||||||
| CAS | 79778-41-9 | ||||||||||||
| Formula | C6H17NO7P2 | ||||||||||||
| Molar Mass | 277.15 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47. [2]. Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827. |